digital currency calculator- Top Overview

After-hours big profits are related to mergers and acquisitions, restructuring, Shanghai state-owned shares have these.According to data treasure statistics, excluding central enterprises and state-owned enterprises, among the above three sectors, there are 41 Shanghai local stocks with a market value exceeding 10 billion yuan.

Since the beginning of this year, favorable policies for mergers and acquisitions have been frequent. Since the CSRC issued the Opinions on Deepening the Market Reform of Listed Companies' M&A and Restructuring on September 24th, the support of all parties to the M&A and restructuring market has continued to increase, and the M&A and restructuring market has continued to be active.Shanghai state-owned companies are expected to directly benefit from the action plan. According to the statistics of Securities Times and Data Treasure, there are 37 A-shares owned by Shanghai State-owned Assets with a market value of less than 10 billion yuan. Among them, the market value of Kaikai Industrial, Chuangchuang International, First Pharmaceutical and other stocks is less than 3 billion yuan, and the market value of Yatong, Changjiang Investment, Changlian, Shanghai Jiubai and *ST Tianwo is less than 4 billion yuan.As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.

It is worth mentioning that among the stocks with a market value of less than 10 billion yuan, Kaikai Industry, Fudan Fuhua, First Hospital and Xuantai Medicine all belong to the biomedical industry. Among the state-owned shares in Shanghai, Hua Hong Company and Hehui Optoelectronics -U belong to the semiconductor industry.Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.